Instrument Inactif

Communiqués GRN Holding Corporation Other OTC

Actions

GRNF

US36257K1097

Recherche biotechnologique et médicale

Communiqués

25/09	NexTel Medical Corp. Showcases Pioneer Exosome Technologies and Diagnostic Innovations at Leading Healthcare Conference	AQ
06/08	NexTel Medical Corp. Clarifies and Expands Upon Remarks Made During Recent Online Discussion	AQ
05/08	NexTel Medical Corp. Executes Letter of Intent to Acquire 100% of Xycota Biosciences, LLC	AQ
28/07	NexTel Medical Corp. Advances Veterinary Oncology Strategy with Rollout of Early-Stage Cancer Screening for Companion Animals	AQ
22/07	NexTel Medical Corp. Amends Previously Announced Acquisition to Acquire Island 40 Group and Full Subsidiary Platform	AQ
17/06	NexTel Medical Outlines its Revenue Model Using the Innovation of Tomorrow: Synergy of Advanced Medical Technologies and Massive Sales Infrastructure Primed to Drive Exponential Growth	AQ
09/06	NexTel Medical Corp. Announces Groundbreaking, First-of-Its-Kind Exosome Characterization Study with Penn State University	AQ
02/06	NexTel Medical Corp. Executes Definitive Purchase Agreements to Acquire JumpstartRx and NueVistraMed, Expanding Telehealth Footprint and Accelerating Maxasome™ Commercialization	AQ
11/05	NexTel Medical Corp Enters Final Stage for Commercial Launch; Sets Sights on Revenue Generation and OTCQB Uplist	AQ
07/04	NexTel Medical Corp Announces Pivotal Milestone in Commercial Launch of Patent-Protected NANOG DNA Cancer Screening Test	AQ
16/03	Exousia Pro, Inc. Announces Favorable Litigation Settlement, Highlighting Significant Debt Elimination and Share Cancellation to Enhance Shareholder Value	AQ
05/03	Exousia Pro, Inc. Announces Strategic Elimination of Future Dilutive Issuance of 47 Million Shares, Progresses Toward Definitive Agreements for Telehealth Acquisitions	AQ
10/02	Exousia Pro, Inc. Accelerates Strategic Expansion with Third Telehealth Acquisition; Strengthens Pathway to Low-Cost Customer Acquisition	AQ
30/04/25	Exousia Pro Will Launch a Web Series with Our New Consultant	AQ
29/04/25	Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead of Schedule - Bolstering Orphan Drug Application	AQ
21/04/25	Exousia Pro CSO Revealed Significant Findings About the Glioblastoma Study in a Spaces Interview	AQ
17/04/25	Exousia Pro Offers Guidance on New Subdivisions	AQ
08/04/25	Exousia Pro to Deliver 500 Billion Dried Exosomes for Trade Show	AQ
03/04/25	Exousia Pro Issues Update on Name Change	AQ
02/04/25	Exousia Pro Has Appointed Matthew Dwyer As Its New President	AQ
01/04/25	Exousia Pro Issues and Update on its FDA Orphan Drug Status	AQ
25/03/25	Exousia Pro Officially Announces the Production of Plant-Based Exosomes Has Begun	AQ
18/03/25	Exousia Has Successfully Renegotiated Its License Agreement	AQ
06/01/25	Marijuana, Inc., Completes Acquisition of Exousia AI and Enters Expanding Exosome Market	PR
26/06/24	GRN Holding Corporation Announces Rebranding to Marijuana Inc. Under the Leadership of the “Henry Ford of the Marijuana Industry,” Donald Steinberg	AQ